Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 25/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: ClaimsFiler has alerted investors of Pacira BioSciences, Inc. regarding a class action lawsuit that they can join if they incurred losses exceeding $100,000 within a specific period. This lawsuit is based on allegations of the company failing to disclose material information that violated federal securities laws. The company recently faced a significant legal setback when a court ruled that its patent related to the Exparel product was invalid, resulting in a drastic fall in share price. Investors have until March 14, 2025, to file for lead plaintiff status in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Legal action against Pacira BioSciences may impact investor confidence.
  • Company charged with failing to disclose material information, violating federal laws.
  • Significant share price drop of over 47% after a patent validity ruling.

Full Press Release Details

NEW ORLEANS, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything. On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file in Pacira's class action lawsuit?

Investors must file lead plaintiff applications by March 14, 2025.

What is the class period for this lawsuit against Pacira?

The class period spans from August 2, 2023, to August 8, 2024.

Why is Pacira facing a securities class action lawsuit?

The company and its executives are accused of failing to disclose critical information.

What significant event affected Pacira's share price?

On August 9, 2024, shares dropped over 47% after a patent ruling against the company.

How can investors get more information about their claims?

Investors can visit ClaimsFiler.com for information and legal discussions.

Last updated: Jan 16, 2025